Latest News

Here you can find all the latest news from the MRC CTU at UCL.

We hosted a successful first meeting of the ACORD Collaboration on Wednesday 8th June 2022.
Having chemotherapy every week does not improve survival for people with ovarian cancer compared to having it once every three weeks.
Adding radiotherapy to standard hormone therapy helps patients with prostate cancer with limited spread of the disease, to live longer.
Docetaxel chemotherapy is substantially more effective for some patients with advanced prostate cancer than others.
Adding the drug abiraterone to standard hormone therapy improves the survival of men with prostate cancer that has spread to other parts of the body.